Osteoarthritis and total knee arthroplasty
Conditions
Interventions
surgicel group:Use of surgicel for wound coverage and intravenous infusion of TXA (Tranexamic Acid) during Total Knee Arthroplasty
Negative control group:Use of Tranexamic Acid (TXA) solution for wound cavity soak prior to joint cavity closure + intravenous infusion of TXA
Control group:Use of Tranexamic Acid (TXA) intravenously only --- a commonly used method for hemostasis in perioperative clinical practice currently.
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) A definitive diagnosis of unilateral or bilateral primary knee osteoarthritis and meets surgical indications. (2) The patient has no past history of open trauma, fracture, or surgery on both knees. (3) Age is =18 years old. (4) Preoperative tests and examinations are essentially normal, with no obvious surgical contraindications; (5) The patient and their family members are willing to participate in this research study, and have signed an informed consent form preoperatively.
Exclusion criteria
Exclusion criteria: (1) Anemia (females <120 g/L, males <130 g/L); (2) Patients with a history of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE); (3) Patients with cardiovascular-related diseases; (4) Patients with congenital or acquired coagulation disorders, or with coagulation abnormalities; (5) Infections: Preoperative presence of an infection focus at the knee joint or elsewhere in the body; (6) Recent use of anticoagulants such as aspirin; (7) The patient or their family members refuse to participate in this research study or refuse to sign the treatment consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total perioperative blood loss blood loss;invisible blood loss;Knee joint color Doppler ultrasound results; | — |
Secondary
| Measure | Time frame |
|---|---|
| Intraoperative dominant blood loss;Number of blood transfusions;Hemoglobin, hematocrit, and albumin;Inflammation markers (C-reactive protein, interleukin-6, erythrocyte sedimentation rate);visual analogue scale; | — |
Countries
China
Contacts
Public ContactXiaojun Shi
West China Hospital, Sichuan University
Outcome results
None listed